Elios Therapeutics

Executive Summary

Elios Therapeutics is a private biotechnology company headquartered in Boston, Massachusetts, founded in 2014 to develop personalized therapeutic cancer vaccines. The company's technology, based on the pioneering work of Dr. Thomas Wagner, utilizes autologous tumor lysate to create a patient-specific vaccine designed to stimulate a targeted and durable immune response against solid tumors. Elios's lead candidate is the Tumor Lysate, Particle Only (TLPO) vaccine, which aims to harness the patient's own immune system to recognize and attack cancer cells. The approach leverages the full antigenic repertoire of the tumor, potentially offering a broader and more personalized immune activation compared to single-antigen vaccines. Despite the promising scientific rationale, Elios Therapeutics remains in early clinical development with limited publicly disclosed data. The company has not disclosed its funding history, valuation, or stage of clinical trials, making it challenging to assess its near-term prospects. The primary risk is the lack of visible clinical results and competitive landscape in personalized cancer vaccines. However, if TLPO demonstrates safety and efficacy in ongoing studies, Elios could become a significant player in the immuno-oncology space. Near-term catalysts include updates from its clinical program, potential regulatory milestones, or strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 Clinical Trial Data Readout for TLPO Vaccine40% success
• Q2 2026FDA Acceptance of Investigational New Drug (IND) Application for Next Trial70% success
• H2 2026Strategic Partnership or Licensing Deal for TLPO30% success